Triple therapy shows significant airway patency improvement in cystic fibrosis patients, suggesting enhanced respiratory health.
Objectives People with Cystic Fibrosis ( CF ) experience significant sinonasal airway opacification, leading to chronic airway‐related conditions. The triple combination therapy Elexacaftor/Tezacaftor/Ivacaftor ( ETI ) has emerged as a therapeutic option for CF . This study uses volumetric quantification technique to evaluate changes in CF sinonasal airway patency pre‐ ETI and post‐ ETI . Methods Anatomically accurate person‐specific three‐dimensional sinonasal airspaces were reconstructed from radiographical images of 19 people (12 male, 7 female) with CF , pre‐ ETI and post‐ ETI . Sinonasal airspace surface area, volume, and surface‐area‐to‐volume ratio were calculated pre‐ ETI and post‐ ETI . Pre‐ ETI and post‐ ETI sinonasal airspace changes in these computed parameters were corrected with changes in both Lund‐Mackay and SNOT ‐22 scores. Results Median ( IQR ) surface area and volume increased significantly from pre‐ ETI (Surface Area: 251.97 cm 2 (43.71); Volume: 44.86 cm 3 (20.72)) to post‐ ETI (Surface Area: 295.77 cm 2 (31.34); Volume: 61.03 cm 3 (14.21)), with respective p < 0.01 per computed parameter. Furthermore, median surface‐area‐to‐volume ratio ( IQR ) was significantly different; pre‐ ETI : 0.053 cm −1 (0.007); post‐ ETI : 0.052 cm −1 (0.013); p = 0.04. Pre‐ ETI to post‐ ETI improvement changes in surface area and volume significantly correlated with corresponding changes in Lund‐Mackay scores (Surface Area: R = −0.78, p < 0.01; Volume: R = −0.68, p < 0.01), but correlated weakly with corresponding changes in patient‐reported SNOT ‐22 scores (Surface Area: R = −0.13, p = 0.62; Volume: R = −0.06, p = 0.82). Conclusion People with CF treated with ETI exhibited a significant increase in sinonasal airway patency, as evidenced by volumetric quantification analysis of surface area and volume differences. These increases in both parameters showed strong significant correlations with Lund‐Mackay scores; however, no such correlations were observed with SNOT ‐22 scores. Level of Evidence 4.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: